It was not that long ago that advanced dry age-related macular degeneration (AMD) was receiving little attention as a target for therapeutic intervention. Evidence of a dramatic shift in this situation was demonstrated by the fact that non-neovascular AMD was a focus for two sessions at the 2024 Euretina Innovation Symposium.

The second annual EURETINA Innovation Spotlight (EIS) held on Wednesday afternoon was a sell-out event, welcoming attendees who learned about the latest innovations in retina from the involved stakeholders.

Retina specialists and researchers in the field who have innovative ideas for new interventions gained insights from representatives of venture capital firms about opportunities and strategies for gaining support.